The study of the assorment of dermatological products for the local treatment of seborrheic dermatitis




marketing research, medicines, medicinal products for local treatment, seborrheic dermatitis


Aim. To perform the analysis of the assortment of medicines, in particular dermatological agents for the treatment of seborrheic dermatitis, which are present at the domestic pharmaceutical market with the subsequent substantiation of the need to develop a new foaming agent.

Materials and methods. The analysis was based on the data of the State Register of Medicinal Products of Ukraine, electronic databases, “Morion” information retrieval program. The logical, system-analytical, comparative methods of analysis were used in the work.

Results. The analysis of the drugs belonging to D01A group “Antifungal preparations for topical administration”, namely the subgroups: D01A C – “Imidazole and triazole derivatives” and D01A E – “Other antifungal agents for topical application” registered at the Ukrainian market has shown that the leading positions are in the subgroup D01A C – “Imidazole and triazole derivatives” (71 %), while the group D01A E – “Other antifungal agents for topical application” has only 29 %. It has been found that the composition of the drugs studied includes 8 synthetic active substances. Derivatives of imidazole, pyrithione, allylamines are the most frequently used. It has been determined that among these medicines monopreparations predominate; some of them are 88 % of the total number of trade names, while only 12 % are combined drugs. Further study of the assortment of the registered producers of antifungal agents for local application by manufacturing countries has shown that 13 countries are registered at the Ukrainian market: India (35 %), Ukraine (32 %), Switzerland (6 %), Belgium, Germany and Turkey (4 %), Spain and Belgium (3 % each). All other manufacturing countries are represented by 2 %. It has been noted that the soft dosage form predominates in the structure of the drugs under study, namely creams – 41 %, ointments – 12 %, gels – 15 %; liquid forms are shampoos – 16 %, solutions for external use – 8 %, spray – 6 %; and there are only 2 % of solids.

Conclusions. Based on the data of the State Register of Medicinal Products of Ukraine it has been found that the total number of drugs of group D01A “Antifungal preparations for topical administration” is 51 trade names. It has been noted that 8 active substances of synthetic origin are presented in the form of monopreparations (88 %) or in combination (12 %) with each other. It has been found that the ratio between imported and domestic medicines is 68 %: 32 %. It has been determined that 41 % of the drugs registered are produced in the form of a cream, 16 % in the form of a shampoo, 15 % in the form of a gel and 12 % in the form of an ointment, while a small part of the preparations is in the form of a solution, a spray and a powder.

Author Biographies

S. V. Zaika, National University of Pharmacy

teaching assistant of the Department of Commodity Science

Y. O. Bezpala, National University of Pharmacy

Candidate of Pharmacy (Ph.D), teaching assistant of the
Department of Commodity Science

K. S. Shmelkova, Kharkiv Medical Academy of Post-graduate Education

Candidate of Medical Sciences, Professor assistant of the Department of Dermatovenereology,

O. P. Shmatenko, Ukrainian Military Medical Academy

MD, Ph.D., DSci., Professor, Head of Department of Military Pharmacy


Skripkin, Yu. K., Butov, Yu. S. (Eds.). (2009). Clinical dermatovenereology: a guide. (2 vols. Vol. 2). Moscow: GEOTAR-Media, 469–475.

Del Rosso, J. Q. (2011). Adult seborrheic dermatitis: a status report on practical topical management. J. Clin. Aesthet. Dermatol., 4 (5), 32–38.

Puzenat, E., Riou-Gotta, M. O., Messikh, R., Humbert, P. (2010). Facial dermatosis: acne, rosacea, seborrhoeic dermatitis Rev. Prat., 60 ( 6), 849–855.

Ileshina, T. V. (2004). Rossiyskiy meditsinskiy zhurnal, 12 (5), 324–326.

Prohic, A., Kasumagic-Halilovic, E. (2010). Identification of Malssezia species from immunocompetent and immunocompromised patient with seborrheic dermatitis. Eur. Rev. Med. Pharmacol. Sci., 14 (12), 1019–1023.

Del Rosso, J. Q., Kim, G. K. (2009). Seborrheic dermatitis and Malassezia species: how are they related? J. Clin. Aesthet. Dermatol., 2 (11), 14–17.

Peyri, J., Lleonart, M. (2007). The Spanish Group of the SEBDERM Study. Clinical and therapeutic profile and quality of life of patients with seborrheic dermatitis. Actas Dermosifiliogr., 98 (7), 476–482.

Rigopoulos, D., Ioannides, D., Kalogeromitros, D. et al. (2004). Pimecrolimus cream 1% vs. beta-methasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. British Journal of Dermatology, 151, 1071–1075.

Metz, M., Wahn, U., Gieler, U. et al. (2013). Chronic pruritus associated with dermatologic disease in infancy and childhood: update from an interdisciplinary group of dermatologists and pediatricians. Pediatric Allergy and Immunology, 24 (6), 527–539.

Meshkinpour, A., Sun, J., Weinstein, G. (2003). An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. JAAD, 49, 145–147.

Belousova, T. A., Horiachkina, M. A., Shranova, D. H. (2013). Bulletin of Dermatology and Venereology, 6, 132–138.

Mikhneva, E. N. (2012). Dermatology and venereology, 2, 44–47.

Derzhavnyi reestr lіkars’kykh zasobіv. On-line versіia. Available at: portal/mtph_register_medicines/.

Kovalenko, V. N. (Ed.). (2017). Kompendium 2016. Lekarstvennye preparaty. Kyiv: MORION, 2270.

Baza dannyh “Lekarstvennie sredstva” OOO “Morion”. Available at:

Piérard-Franchimont, C., Goffin, V., Decroix, J., Piérard, G. E. (2002). A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacol Appl Skin Physiol., 15, 434–441.





Social marketing and pharmacoeconomic research